[CH2:1]([O:3][CH2:4][C@H:5]([NH:26]C(=O)OC(C)(C)C)[CH2:6][NH:7][C:8]1[N:13]=[C:12]([NH:14][C:15]2[CH:16]=[C:17]([CH3:21])[CH:18]=[CH:19][CH:20]=2)[C:11]2[C:22](=[O:25])[NH:23][CH2:24][C:10]=2[CH:9]=1)[CH3:2].CCOC(C)=O.C1COCC1>C(Cl)Cl>[NH2:26][C@@H:5]([CH2:4][O:3][CH2:1][CH3:2])[CH2:6][NH:7][C:8]1[N:13]=[C:12]([NH:14][C:15]2[CH:16]=[C:17]([CH3:21])[CH:18]=[CH:19][CH:20]=2)[C:11]2[C:22](=[O:25])[NH:23][CH2:24][C:10]=2[CH:9]=1To a solution of (R)-tert-butyl 1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate (109 mg, 0.239 mmol) in DCM (1 mL) was added a TFA/DCM solution (1/1, 10 mL). The mixture was stirred at RT for 2 h. After removal of the solvent, the resulting crude material was reconstituted in a solution of MeOH/DCM (1/1, 5 mL) and was purified via reverse phase preparative HPLC. The fractions were collected, and ACN was removed via rotary evaporation. The resulting aq solution was neutralized with saturated aq NaHCO3, washed with EtOAc (2×200 mL), dried over Na2SO4, and filtered. The organic phase was stripped to dryness via rotary evaporation to give the title compound (11 mg, 13%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.08-1.18 (m, 3 H), 1.25-1.44 (m, 4 H), 2.26-2.32 (m, 3 H), 4.07-4.17 (m, 3 H), 4.19-4.29 (m, 2 H), 6.03 (s, 1 H), 6.78 (d, J=7.83 Hz, 1 H), 7.06 (br s, 1 H), 7.12-7.22 (m, 1 H), 7.48 (s, 1 H), 7.60 (d, J=7.83 Hz, 1 H), 7.66-7.75 (m, 2 H), 7.99 (s, 1 H), 8.83-8.97 (m, 1 H). [M+H] calc'd for C19H25N5O2, 356; found, 356.
불러오는 중…